Global study estimates over 250,000 meningitis deaths in 2023, with young children bearing a heavy toll
medicalxpress - In 2023, 259,000 people died from meningitis and 2.5 million people were infected with the disease globally, suggests a study published in The Lancet Neurology. Although death and infection rates have declined significantly since 1990, progress is insuffi…
AI Summary: A worldwide mortality analysis estimates more than 250,000 deaths from meningitis in 2023, with young children bearing the heaviest toll. The findings underline gaps in vaccination, surveillance and outbreak preparedness, and call for accelerated prevention efforts—particularly on campuses and in high‑risk populations—before the predictable heartbreak rolls around again.
Two States Sue Cord Blood Bank Over False Advertisements
Sarah Kliff and Azeen Ghorayshi / nytimes - The attorneys general of Texas and Arizona contend that Cord Blood Registry, which stores umbilical cord cells, profited from misleading new parents.
AI Summary: Two state attorneys general filed lawsuits alleging a cord‑blood bank made false or misleading claims about the future therapeutic value of stored units. The actions seek consumer remedies and penalties, challenging marketing that regulators say may have led families to pay for services based on overstated promises about potential medical uses.
UK government recommends maximum two hours of screen time for younger children: What the evidence says
medicalxpress - New UK government guidance recommends that screen time for children under two should be avoided, except for shared activities such as video calls. For children aged two to five, a maximum of an hour a day is suggested. The guidance also outlines that watc…
AI Summary: The UK government updated child‑health guidance recommending strict limits on young children’s screen time, citing evidence linking excessive use to delayed development and poorer sleep. The guidance urges parents and caregivers to prioritize interactive, non‑screen activities and age‑appropriate limits while acknowledging modern practicalities for families.
FDA approves Rocket's gene therapy for ultra-rare immune disease
Lei Lei Wu / endpoints - A rare disease gene therapy from Rocket Pharmaceuticals has garnered FDA approval after an earlier rejection for manufacturing problems. The FDA on Thursday granted accelerated approval to Rocket Pharma’s gene therapy ...
AI Summary: The FDA granted approval to Rocket’s gene therapy for a pediatric immune disorder, marking the first regulatory ok for this specific treatment class in children and offering a one‑time corrective option for affected patients. The decision opens access while raising expectations for long‑term follow‑up and real‑world safety monitoring.